ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Pramipexole

Also written as “pramipexole”, “Pramipexole Dihydrochloride” and “Pramipexole Immediate Release”.

Its studies are mostly in Parkinson Disease · Restless Legs Syndrome · Tourette Syndrome · Depressive Disorder, Major · Obsessive-Compulsive Disorder, led by 6 companies.

Drug pagePramipexole: every studyMany companies study it; this page follows only the 43 they lead. All 81 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Sep 2, 200543 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Boehringer Ingelheim360 open or runningphase 4since Sep 2, 2005Aug 22, 2005none ahead
Teva Pharmaceutical Industriesits history only30 open or runningphase 4since Nov 10, 2006Nov 10, 2006none ahead
Chase Therapeuticsits history only11 open or runningphase 2since Jul 5, 2018Jul 5, 2018none ahead
GlaxoSmithKlineits history only10 open or runningphase 1since May 8, 2007May 8, 2007none ahead
Haisco Pharmaceutical Groupits history only10 open or runningphase 1since Apr 2, 2026Apr 2, 2026none ahead
Novartisits history only10 open or runningphase 4since Aug 23, 2012Aug 23, 2012none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 18 studies since Aug 22, 2005.

  1. Nov 12, 20072 phase 3 studies in Parkinson DiseaseNCT00558025, NCT00560508
  2. Nov 14, 2007Phase 2 study in Tourette SyndromeNCT00558467 · 63 enrolled · United States, Germany
  3. Dec 19, 2007Phase 3 study in Parkinson DiseaseNCT00577460 · 391 enrolled · Austria, Czech Republic, Hungary and more
  4. Jan 15, 2008Phase 3 study in Parkinson DiseaseNCT00601523 · 511 enrolled · United States, Austria, Czech Republic and more
  5. Mar 27, 2008Phase 3 study in Restless Legs SyndromeNCT00654498 · 306 enrolled · China
  6. May 19, 2008Phase 3 study in Tourette SyndromeNCT00681863 · 45 enrolled · United States, Germany
  7. May 29, 2008Phase 2 study in FibromyalgiaNCT00689052 · 61 enrolled · United States
  8. Aug 30, 2010Phase 3 study in Parkinson DiseaseNCT01191944 · 475 enrolled · China
  9. Oct 1, 2010Phase 1 study in HealthyNCT01214109 · 24 enrolled · China
  10. Jun 20, 20142 phase 3 studies in Parkinson DiseaseNCT02172573, NCT02177357
  11. Sep 4, 2014Phase 4 study in Parkinson DiseaseNCT02233023 · 705 enrolled
  12. Oct 9, 20143 phase 1 studies in HealthyNCT02262546, NCT02261103, NCT02264132
  13. Apr 11, 2018Phase 4 study in Parkinson DiseaseNCT03521635 · 98 enrolled · China
  14. Jul 22, 2026Phase 1 study in HealthyNCT07727785 · 25 enrolled · Germany

TargetBeta

“D2-like dopamine receptor agonist”ChEMBL 37, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
OlanzapineruleEli Lillyphase 476
rotigotineruleUCBphase 464

Studies

All 36 Boehringer Ingelheim leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07727785Healthy · Germany1CompletedSep 10, 202625
NCT03521635Parkinson Disease · China4CompletedJan 7, 202098
NCT02264132Healthy1CompletedNov 200624
NCT02262546Healthy1CompletedOct 200760
NCT02261103Healthy1CompletedJul 200639
NCT02233023Parkinson Disease4CompletedJun 2000705
NCT02177357Parkinson Disease3CompletedJan 2000150
NCT02172573Parkinson Disease3CompletedJul 2000315
NCT01214109Healthy · China1CompletedJan 201124
NCT01191944Parkinson Disease · China3CompletedJan 2012475
NCT00689052Fibromyalgia · United States2TerminatedNov 200861
NCT00681863Tourette Syndrome · United States, Germany3TerminatedOct 200945
NCT00654498Restless Legs Syndrome · China3CompletedJun 2009306
NCT00601523Parkinson Disease · United States, Austria, Czech Republic and more3CompletedJun 2010511
NCT00577460Parkinson Disease · Austria, Czech Republic, Hungary and more3CompletedJun 2010391
NCT00560508Parkinson Disease · Japan3CompletedNov 2009112
NCT00558467Tourette Syndrome · United States, Germany2CompletedJun 200963
NCT00558025Parkinson Disease · France, Germany, Netherlands3CompletedMay 2008156
NCT00479401Parkinson Disease · United States, Argentina, Austria and more3CompletedNov 2008539
NCT00472199Restless Legs Syndrome · Austria, Belgium, Finland and more4CompletedJul 2008331
NCT00466167Parkinson Disease · Austria, Czech Republic, Hungary and more3CompletedNov 2008517
NCT00402233Parkinson Disease · United States4CompletedSep 2008312
NCT00390689Idiopathic Restless Legs Syndrome · Japan3CompletedMar 2008154
NCT00375284Restless Legs Syndrome · United States4CompletedJul 2007404
NCT00356096Restless Legs Syndrome · Finland, France, Germany and more4CompletedJun 2007404
NCT00349531Restless Legs Syndrome · Denmark, Finland, Germany and more4CompletedMay 2007369
NCT00321854Parkinson Disease · United States, Austria, Finland and more4CompletedApr 2009535
NCT00297778Parkinson Disease · Austria, Finland, France and more4CompletedMay 2008296
NCT00275457Restless Legs Syndrome · Austria, Germany, Netherlands and more3CompletedApr 2004346
NCT00240409Parkinson Disease · China3CompletedAug 2004208
NCT00239486Restless Legs Syndrome · Finland2CompletedApr 2004109
NCT00152997Restless Legs Syndrome · Japan2CompletedDec 200541
NCT00152958Restless Legs Syndrome · Germany3CompletedFeb 2005224
NCT00144300Parkinson Disease · United States4CompletedSep 2010246
NCT00144209Restless Legs Syndrome · Switzerland3CompletedFeb 200558
NCT00133198Restless Legs Syndrome · United States3CompletedFeb 2005345

How it is read

Names in the registry

  • “Pramipexole”, 15 entries
  • “pramipexole”, 5 entries
  • “Pramipexole Dihydrochloride”, 4 entries
  • “Pramipexole Immediate Release”, 2 entries
  • “Pramipexole Extended Release”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.